Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rosnilimab · 2 trials · 2 indications
The mMS is an endoscopic and clinical scale, which ranges in scores from 0-9, with higher numbers indicating increased disease severity. It is used to assess UC disease activity. It consists of three subscores: RBS, SFS and an endoscopy subscore.
The DAS28-CRP is a validated composite assessment that assesses RA disease activity based on tender and swollen joint counts of 28 joints
| Arm | Type | Description |
|---|---|---|
| Rosnilimab SC Dose 1 | EXPERIMENTAL | This arm will receive High dose Rosnilimab SC |
| Rosnilimab SC Dose 2 | EXPERIMENTAL | This arm will receive low dose Rosnilimab SC |
| Placebo | PLACEBO_COMPARATOR | This arm will receive Placebo SC |
| Rosnilimab SC Dose 3 | EXPERIMENTAL | This arm will receive treatment SC |
| Name | Type | Description |
|---|---|---|
| Rosnilimab | DRUG | PD-1 agonist antibody |
| Placebo | DRUG | Administered via SC |
Inclusion Criteria: * Male or female ≥18 * Participants with a clinical diagnosis of UC for prior to Day 1 * Subject has moderate to severe, active UC, defined as a mMS ≥ 5 with an endoscopy subscore ≥2 * Subject has had a surveillance colonoscopy that did not detect potential dysplasia or colon ca...
Top 20 of 27 competitors
Rosnilimab is an investigational antibody being developed for moderate to severe rheumatoid arthritis and moderate to severe ulcerative colitis. It is currently in Phase 2 clinical trials for both indications.
Rosnilimab is a monoclonal antibody, indicated by its -mab suffix. It is being studied for its efficacy and safety in treating autoimmune conditions like rheumatoid arthritis and ulcerative colitis, though its specific molecular target is not disclosed in available information.
Rosnilimab is being developed by AnaptysBio, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ANAB.
Rosnilimab is in Phase 2 clinical development. It is not approved by regulatory authorities and remains investigational, with active trials ongoing for rheumatoid arthritis and ulcerative colitis.
Rosnilimab is being studied in two Phase 2 trials: NCT06041269, known as RENOIR, for moderate to severe rheumatoid arthritis with 420 participants, and NCT06127043, known as ROSETTA, for moderate to severe ulcerative colitis with 132 participants. Both are active but not recruiting.